Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Bejon

Showing results (221-230 of 276) with videos related to

Pageof 28
Sort By:
BMJ Global Health|August 1, 2022
Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in KenyaStacey Orangi, John Ojal, Samuel Pc Brand, et al.
The Lancet. Infectious Diseases|January 18, 2011
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trialAlly Olotu, John Lusingu, Amanda Leach, et al.
Wellcome Open Research|December 14, 2022
Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test dataJohn Ojal, Samuel P C Brand, Vincent Were, et al.
BMC Medicine|January 27, 2022
Malaria hospitalisation in East Africa: age, phenotype and transmission intensityAlice Kamau, Robert S Paton, Samuel Akech, et al.
Wellcome Open Research|December 6, 2024
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational studyJohn Kimotho, Yiakon Sein, Shahin Sayed, et al.
The Lancet. Infectious Diseases|June 10, 2021
Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trialMainga Hamaluba, Rob W van der Pluijm, Joseph Weya, et al.
BMC Infectious Diseases|December 28, 2024
Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in KenyaDoreen Lugano, Bernadette Kutima, Makobu Kimani, et al.
Lancet (London, England)|April 7, 2024
Feasibility, safety, and impact of the RTS,S/AS01<sub>E</sub> malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and MalawiKwaku Poku Asante, Don P Mathanga, Paul Milligan, et al.
Frontiers in Immunology|January 9, 2019
KILchip v1.0: A Novel <i>Plasmodium falciparum</i> Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate PrioritizationGathoni Kamuyu, James Tuju, Rinter Kimathi, et al.
The New England Journal of Medicine|December 10, 2008
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of agePhilip Bejon, John Lusingu, Ally Olotu, et al.
Pageof 28

Showing results (221-230 of 276) with videos related to

Sort By:
Pageof 28
BMJ Global Health|August 1, 2022
Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in KenyaStacey Orangi, John Ojal, Samuel Pc Brand, et al.
The Lancet. Infectious Diseases|January 18, 2011
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trialAlly Olotu, John Lusingu, Amanda Leach, et al.
Wellcome Open Research|December 14, 2022
Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test dataJohn Ojal, Samuel P C Brand, Vincent Were, et al.
BMC Medicine|January 27, 2022
Malaria hospitalisation in East Africa: age, phenotype and transmission intensityAlice Kamau, Robert S Paton, Samuel Akech, et al.
Wellcome Open Research|December 6, 2024
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational studyJohn Kimotho, Yiakon Sein, Shahin Sayed, et al.
The Lancet. Infectious Diseases|June 10, 2021
Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trialMainga Hamaluba, Rob W van der Pluijm, Joseph Weya, et al.
BMC Infectious Diseases|December 28, 2024
Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in KenyaDoreen Lugano, Bernadette Kutima, Makobu Kimani, et al.
Lancet (London, England)|April 7, 2024
Feasibility, safety, and impact of the RTS,S/AS01<sub>E</sub> malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and MalawiKwaku Poku Asante, Don P Mathanga, Paul Milligan, et al.
Frontiers in Immunology|January 9, 2019
KILchip v1.0: A Novel <i>Plasmodium falciparum</i> Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate PrioritizationGathoni Kamuyu, James Tuju, Rinter Kimathi, et al.
The New England Journal of Medicine|December 10, 2008
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of agePhilip Bejon, John Lusingu, Ally Olotu, et al.
Pageof 28